On December 27, 2020, the first batch of guidelines for the standardization project of the "Guidelines for the Treatment of Advantageous Diseases of Chinese Patent Medicines" was held at the Beijing Convention Center. The guidelines are the first in my country to target general practitioners and western physicians to guide clinical practice. Evidence-based practice guidelines for the rational use of proprietary Chinese medicines. The project was approved by State Administration of Traditional Chinese Medicine (project number: SATCM—2015—BZ[402]), the project undertaker China Association of Chinese Materia Medica, project leader, researcher Fang Shuting, chief expert Zhang Boli academician, Professor Gao Xuemin, Professor Tian Jinzhou, the project executive team leader, and Professor Li Youping, the quality control team leader. At present, the project has established guidelines for 45 dominant diseases, and more than 1,800 medical institutions and more than 2,000 Chinese and Western medicine clinical experts have coordinated research.
Fang Shuting, former president of China Association of Traditional Chinese Medicine and former deputy director of State Administration of Traditional Chinese Medicine presided over the press conference. The heads of relevant departments such as the State Administration of Traditional Chinese Medicine, the National Health Commission, and the State Food and Drug Administration attended the press conference. The chief expert of the project, the People’s Hero Academician Zhang Boli, the Chairman of the Academic Committee, Academician Chen Keji, Professor Gao Xuemin, Professor Tian Jinzhou, Professor Wei Lihui, More than 100 representatives of Chinese and Western medicine experts from across the country, including Professor Ma Rong, Professor Shen Kunling, Professor Lin Jiangtao, and Professor Z6z Mao Jingyuan, attended the press conference. Also present at the press conference were heads of institutions such as the China Center for Evidence-based Medicine, Tianjin University of Traditional Chinese Medicine Center for Evidence-Based Medicine, corporate representatives and related media. At the press conference of
, the People’s Hero and Academician Zhang Boli of the Chinese Academy of Engineering gave the guide release address, explaining the characteristics and value of the guide project; the national famous teaching teacher Gao Xuemin explained the background of the "Guide" project; the Yangtze River scholar Professor Tian Jinzhou introduced the key technology and innovation of the "Guide" The nature and limitations; People’s Daily Director Wang Junping conducted an on-site dialogue and interview around the release of the guide.
Standardization project kick-off meeting of "Guidelines for Clinical Application of Proprietary Chinese Medicines in the Treatment of Advantageous Diseases"
1. Project background
Chinese patent medicines are mostly prescribed and used by Western physicians. There is a certain phenomenon of irrational use of medicines, which affects the efficacy of Chinese patent medicines and poses some safety risks. The TCM guidelines mostly directly refer to TCM dialectical terms to recommend proprietary Chinese medicines; the Western Medicine Guide neither recommends TCM decoctions nor recommends proprietary Chinese medicines.
To solve the above problems, in 2015, the China Association of Chinese Materia Medica was commissioned by the State Administration of Traditional Chinese Medicine to study and formulate a study that not only follows the practice of Western medicine disease diagnosis and treatment, but also respects the characteristics of TCM syndrome differentiation and treatment. It is supported by evidence-based evidence so that Western medicine can understand and be easy to understand. Master and use the clinical evidence-based practice guidelines for proprietary Chinese medicines-"Guidelines for the clinical application of proprietary Chinese medicines in the treatment of dominant diseases".
2. Guidelines tasks and development process
The project plans to complete 60 "Clinical Application Guidelines for the Treatment of Advantageous Types of Chinese Patent Medicines", 20 Clinical Application Guidelines for Classical Famous Chinese Patent Medicines, and 5 Syndrome Clinical Application Guidelines for Chinese Patent Medicines. The first batch of 14 guidelines united 561 medical institutions and 785 experts across the country to participate in the development. It took 5 years and the research was mature. It was released today. This series of guidelines follows the development of international evidence-based guidelines and combines the characteristics of traditional Chinese medicine. The first batch of guidelines issued 187,668 original studies included 1,500 studies that met the standards, completed 783 systematic reviews meta-analysis, and formed 177 main recommendations. Finally, 107 Chinese patent medicines were recommended from 1363 Chinese patent medicines.
Standardized Project Management Work Meeting of "Guidelines for the Clinical Application of Chinese Patent Medicines for the Treatment of Advantageous Diseases"
3. Guidelines Promotion Plan
This first batch of Chinese patent medicines is issued to treat vascular dementia, coronary heart disease, ventricular premature contractions, acute upper respiratory infections in children, The 14 guidelines for neonatal jaundice and adult influenza have been collated with the Chinese Journal of Integrated Traditional Chinese and Western Medicine and will be officially published soon. In order to strengthen the publicity and application of the guidelines, the China Association of Chinese Materia Medica is applying to the Medical Management Center of the National Health Commission to enter the first batch of guidelines into the Chinese clinical practice optimization knowledge base; in conjunction with the China Population Welfare Foundation "Chinese Medicine and Chinese Medicine Public Welfare Cloud Class" project, Election of clinical experts to popularize the guidelines to the public. At the same time, the association will also actively play the role ofThe team advantage of famous Chinese and Western medicine clinical experts conducts the applicability evaluation of the guidelines and training and publicity.
"Guidelines for Clinical Application of Proprietary Chinese Medicines in the Treatment of Advantageous Diseases" Standardization Project Technical Review Meeting
People's Hero, "Clinical Application Guidelines for Proprietary Chinese Medicines in the Treatment of Advantageous Diseases" Standardization Project Chief Expert Zhang Boli made a speech:
The standardization project expert group of "Guidelines for the Clinical Application of Chinese Patent Medicines for the Treatment of Advantageous Diseases" issued the first batch of guidelines.
Adhering to equal emphasis on Chinese and Western medicine is a basic policy of China's medical and health work. Adhering to the combination of Chinese and Western medicine and the combined use of Chinese and Western medicine becomes a prevention A major feature of the control of the new crown pneumonia epidemic is the vivid practice of traditional Chinese medicine inheritance and innovation. In order to guide clinicians to use Chinese patent medicines more rationally, and to give full play to the clinical value of Chinese medicine, in October 2015, the State Administration of Traditional Chinese Medicine approved a project Initiated the standardization project of "Guidelines for the Clinical Application of Chinese Patent Medicines for the Treatment of Advantageous Diseases" (SATCM-2015—BZ[402]), established a total of 45 guidelines for advantageous diseases, and organized 1,800 units and 2,000 Chinese and Western medicine experts across the country to coordinate research.
The batch of 14 guidelines united 561 medical institutions across the country and 785 experts participated in the development. It took 5 years and the research was mature. It was released today. This series of guidelines follows the development of international evidence-based guidelines and combines the characteristics of traditional Chinese medicine. From 187,688 original studies 1500 studies that met the criteria were included, 783 systematic reviews were completed, and 177 main recommendations were formed. Finally, 107 Chinese patent medicines were recommended from 1363 Chinese patent medicines.
This guide has the following characteristics:
1. Treating superior diseases with proprietary medicines demonstrates the clinical value of traditional Chinese medicine. Traditional Chinese and Western medicines have their own strengths, but also have their own shortcomings or shortcomings. The diseases selected in this guide are in line with the treatment of traditional Chinese medicine, have advantages, and can improve patient benefits. To better demonstrate the clinical value of traditional Chinese medicine.
2. Develop precise and personalized recommendations for proprietary Chinese medicines. On the basis of disease differentiation and dialectics, develop different links around disease staging, classification, syndromes, and symptoms, and clarify medication Indications, a recommendation model that reflects the precise and personalized features of Chinese patent medicines, and is especially suitable for clinical application by Western physicians, general practitioners and primary medical workers.
3. Adhere to the combination of evidence-based medicine principles and traditional Chinese medicine characteristics, and innovative recommendations Principles. The formation of the recommendation principle of evidence-based, consensus as supplementary, and experience as a reference not only conforms to the general principles of evidence-based guidelines, but also takes into account the clinical characteristics of the evidence system of traditional Chinese medicine.
4. The research method is scientific and rigorous, and the evidence is recommended by classification. Has important clinical significance. Innovative recommended evaluation procedures, scientific methods Rigorous, based on the level of evidence and clinical value currently obtained, to adopt graded recommendations, which is conducive to the selection and use of clinicians, and has important clinical significance.
The research and release of this guide is a specific measure to implement the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine", which is of great significance and exemplary role in promoting the "high-quality" development of Chinese medicine.
1. The formulation and application of the guidelines will improve the clinical rational use of Chinese patent medicines, guarantee and improve the clinical efficacy, benefit patients while reducing waste of resources, which is conducive to the healthy development of medical reform and medical insurance policies;
2. The application reflects the requirements of the times of technological innovation and self-reliance of science and technology, with enterprises as the main body of innovation, which will promote the research and development of new Chinese medicines and the high-quality development of the industry, and accelerate the process of going international;
3. The formation of an innovative team integrating traditional Chinese and Western medicine and multidisciplinary cross integration will accelerate the integration of traditional Chinese and Western medicine and give equal emphasis to traditional Chinese and Western medicine. Although the work of
"Clinical Application Guidelines for the Treatment of Advantageous Diseases of Chinese Patent Medicines" has undergone 5 years of repeated consideration and revision, there are still certain limitations and deficiencies.
If the guideline is only based on the best evidence currently available, it recommends the use of proprietary Chinese medicines for disease or a certain link with a clear advantage, and does not cover certainAll the clinical problems of this disease cannot replace the treatment guidelines of the disease; the small amount of high-quality clinical research literature of Chinese patent medicines affects the strength of the evidence for recommendation. However, it provides a clear direction and demand for our follow-up more targeted evidence-based production of high-quality evidence.
To sum up, the publicity and implementation of the guideline and the applicability evaluation of the guideline should be strengthened. And with the emergence of new evidence, timely revision and improvement of the guidelines, and strive for continuous improvement, stop at the best. "Z3z
4. Limitations and deficiencies of the guidelines
1. The guidelines are based only on the best evidence currently available and recommend the use of proprietary Chinese medicines for diseases or certain links with clear advantages. They do not cover all clinical problems of a disease and cannot replace the disease. Z3z
2. The number of clinical high-quality research literature on proprietary Chinese medicines is small, which affects the strength of the recommended evidence;
3. Chinese patent medicines not recommended by the guidelines are mainly due to: no high-quality evidence support, evidence support, but expert consensus does not meet the recommendation Standard, although it is a classic prescription or widely used but not supported by evidence, although it is the same variety but without evidence to support the dosage form and specification;
4. Some recommendations still adopt a single traditional model, which may be "understandable and easy to use" for Western physicians There is a certain challenge.
In this regard, after the release of the guide, it is necessary to do a good job in publicity and applicability assessment, and as new evidence is generated, the guide should be revised and improved in time, and strive for continuous improvement, and stop at perfection. Academician Chen Keji of
Experts on behalf of the conference said: The "Guidelines for the Clinical Application of Chinese Patent Medicines in the Treatment of Advantageous Diseases" is China's first evidence-based practice guide for Chinese patent medicines, which is mainly targeted at general practitioners and western doctors, and is jointly researched and compiled by Chinese and Western medicine experts. The guideline project leverages the synergistic advantages of Chinese and Western medicine experts to form a decision-making model that integrates "experience" and "evidence", promotes the leap from "clinical drug selection" to "evidence-based drug use", highlights the unique advantages of Chinese medicine, and promotes the formation of a combination of Chinese and Western medicine The medication plan enhances Western medicine's awareness of traditional Chinese medicine, helps to improve the plight of restricted use of Chinese patent medicines in medical institutions, promotes the formation of a collaborative, multidisciplinary research team that integrates traditional Chinese and Western medicine, and promotes the integration of Chinese and Western medicine , Pay equal attention to Chinese and Western medicine, and promote the upright and innovative development of Chinese medicine.
